NASDAQ:PSNL Personalis Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Personalis Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $23.80 +0.23 (+0.98 %) (As of 09/22/2020 02:18 PM ET) Add Compare Share Today's Range$22.63Now: $23.80▼$23.8550-Day Range$17.41MA: $21.63▼$24.1252-Week Range$4.27Now: $23.80▼$24.87Volume9,931 shsAverage Volume425,251 shsMarket Capitalization$758.86 millionP/E RatioN/ADividend YieldN/ABeta1.91 ProfileAnalyst RatingsChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesShort InterestSocial Media Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT platform, a clinical-grade, next generation sequencing and analysis platform that enables the development of ImmunoID NeXT tumor biopsy and liquid biopsy, as well as provides analysis of tumor and immune microenvironment from a single limited tissue sample, tumor molecular profiling for cancer patients, and anticipates future cancer biomarkers. The company also provides accuracy and content enhanced platform (ACE) that enhances nucleic acid preparation processes and combines it with patented assay and sequencing methods. ACE Platform offers multiple products and services, such as ACE extended cancer panel for DNA and RNA, and ACE cancer research Exome and Transcriptome. In addition, it develops NeXT Dx test, which helps oncologists to identify potential therapies and clinical trial options for cancer patients, as well as offers whole genome sequencing, which provides DNA sequencing and data analysis services; and ACE CancerPlus Test. The company also provides a liquid biopsy assay that analyzes various human genes versus the more narrowly focused liquid biopsy assays that are currently available. It serves approximately 50 biopharmaceutical customers, including a range of pharmaceutical companies. The company was founded in 2011 and is headquartered in Menlo Park, California.Read More Beat the Market (BTM) Rank™ 1.5 Analyst's Opinion Consensus RatingPersonalis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $25.20, Personalis has a forecasted upside of 5.9% from its current price of $23.80.Amount of Analyst CoveragePersonalis has only been the subject of 4 research reports in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesPersonalis has received 68 “outperform” votes. (Add your “outperform” vote.)Underperform VotesPersonalis has received 60 “underperform” votes. (Add your “underperform” vote.)Community SentimentPersonalis has received 53.13% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Personalis and other stocks. Vote “Outperform” if you believe PSNL will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PSNL will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldPersonalis does not currently pay a dividend.Dividend GrowthPersonalis does not have a long track record of dividend growth. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Personalis insiders have bought 25.21% more of their company's stock than they have sold. Specifically, they have bought $24,999,991.00 in company stock and sold $19,966,115.00 in company stock.Percentage Held by InsidersOnly 8.20% of the stock of Personalis is held by insiders.Percentage Held by Institutions61.62% of the stock of Personalis is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Personalis are expected to grow in the coming year, from ($1.15) to ($1.08) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Personalis is -23.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Personalis is -23.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPersonalis has a P/B Ratio of 6.96. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 1.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.57 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PSNL Previous Symbol CUSIPN/A CIKN/A Webwww.personalis.com Phone650-752-1300Debt Debt-to-Equity RatioN/A Current Ratio2.79 Quick Ratio2.64Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$65.21 million Price / Sales11.64 Cash FlowN/A Price / Cash FlowN/A Book Value$3.42 per share Price / Book6.96Profitability EPS (Most Recent Fiscal Year)($1.39) Net Income$-25,080,000.00 Net Margins-43.16% Return on Equity-31.11% Return on Assets-20.78%Miscellaneous Employees181 Outstanding Shares31,885,000Market Cap$758.86 million Next Earnings Date11/11/2020 (Estimated) OptionableNot Optionable $23.80 +0.23 (+0.98 %) (As of 09/22/2020 02:18 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive PSNL News and Ratings via Email Sign-up to receive the latest news and ratings for PSNL and its competitors with MarketBeat's FREE daily newsletter. Personalis (NASDAQ:PSNL) Frequently Asked Questions How has Personalis' stock been impacted by COVID-19? Personalis' stock was trading at $6.02 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, PSNL stock has increased by 290.4% and is now trading at $23.50. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Personalis? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Personalis in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Personalis. When is Personalis' next earnings date? Personalis is scheduled to release its next quarterly earnings announcement on Wednesday, November 11th 2020. View our earnings forecast for Personalis. How were Personalis' earnings last quarter? Personalis (NASDAQ:PSNL) issued its quarterly earnings results on Thursday, August, 6th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.34) by $0.05. The firm earned $19.50 million during the quarter, compared to the consensus estimate of $17.05 million. Personalis had a negative net margin of 43.16% and a negative return on equity of 31.11%. View Personalis' earnings history. What price target have analysts set for PSNL? 5 analysts have issued 12-month price objectives for Personalis' shares. Their forecasts range from $22.00 to $30.00. On average, they expect Personalis' share price to reach $25.20 in the next twelve months. This suggests a possible upside of 7.2% from the stock's current price. View analysts' price targets for Personalis. Who are some of Personalis' key competitors? Some companies that are related to Personalis include Burning Rock Biotech (BNR), CareDx (CDNA), Veracyte (VCYT), Castle Biosciences (CSTL), Genetron (GTH), Fulgent Genetics (FLGT), RadNet (RDNT), ALX Oncology (RNLX), Progenity (PROG), Centogene (CNTG), DermTech (DMTK), Enzo Biochem (ENZ), Biocept (BIOC), Celcuity (CELC) and Anpac Bio-Medical Science (ANPC). View all competitors. What other stocks do shareholders of Personalis own? Based on aggregate information from My MarketBeat watchlists, some companies that other Personalis investors own include Enphase Energy (ENPH), Pfizer (PFE), AbbVie (ABBV), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX), NIO (NIO), NVIDIA (NVDA), Boeing (BA), QUALCOMM (QCOM) and Viking Therapeutics (VKTX). Who are Personalis' key executives? Personalis' management team includes the following people: Mr. John Stephen West, Co-Founder, CEO, Pres & Director (Age 63, Pay $785.44k)Mr. Aaron L. Tachibana, Chief Financial Officer (Age 59, Pay $494.4k)Dr. Richard Chen M.S., M.D., MS, Chief Scientific Officer (Age 49, Pay $543.75k)Prof. Russ B. Altman, Co-Founder and Member of Clinical & Scientific Advisory BoardMr. Euan A. Ashley, Co-Founder and Member of Clinical & Scientific Advisory Board When did Personalis IPO? (PSNL) raised $100 million in an initial public offering on Thursday, June 20th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen and Company acted as the underwriters for the IPO and Oppenheimer was co-manager. What is Personalis' stock symbol? Personalis trades on the NASDAQ under the ticker symbol "PSNL." Who are Personalis' major shareholders? Personalis' stock is owned by many different retail and institutional investors. Top institutional investors include Wellington Shields & Co. LLC (3.28%), Sumitomo Mitsui Trust Holdings Inc. (2.53%), Board of Trustees of The Leland Stanford Junior University (2.31%), Wellington Shields Capital Management LLC (1.73%), Candriam Luxembourg S.C.A. (1.65%) and Gabelli Funds LLC (0.77%). Company insiders that own Personalis stock include Aaron Tachibana, Ken Ludlum, Lightspeed Venture Partners Se, Llp Abingworth and Richard Chen. View institutional ownership trends for Personalis. Which institutional investors are selling Personalis stock? PSNL stock was sold by a variety of institutional investors in the last quarter, including Board of Trustees of The Leland Stanford Junior University, Sumitomo Mitsui Trust Holdings Inc., Prosight Management LP, Gabelli Funds LLC, Federated Hermes Inc., Strs Ohio, Alyeska Investment Group L.P., and Bank of Montreal Can. Company insiders that have sold Personalis company stock in the last year include Aaron Tachibana, Ken Ludlum, Llp Abingworth, and Richard Chen. View insider buying and selling activity for Personalis. Which institutional investors are buying Personalis stock? PSNL stock was bought by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Cadence Capital Management LLC, Wellington Shields & Co. LLC, Engineers Gate Manager LP, California Public Employees Retirement System, Parallel Advisors LLC, Jacobs Levy Equity Management Inc., and Nuveen Asset Management LLC. Company insiders that have bought Personalis stock in the last two years include Ken Ludlum, and Lightspeed Venture Partners Se. View insider buying and selling activity for Personalis. How do I buy shares of Personalis? Shares of PSNL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Personalis' stock price today? One share of PSNL stock can currently be purchased for approximately $23.50. How big of a company is Personalis? Personalis has a market capitalization of $749.30 million and generates $65.21 million in revenue each year. The company earns $-25,080,000.00 in net income (profit) each year or ($1.39) on an earnings per share basis. Personalis employs 181 workers across the globe. What is Personalis' official website? The official website for Personalis is www.personalis.com. How can I contact Personalis? Personalis' mailing address is 1330 O`BRIEN DRIVE, MENLO PARK CA, 94025. The company can be reached via phone at 650-752-1300 or via email at [email protected] This page was last updated on 9/22/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
